Technology Fees was Biotricity’s largest product and service line in fiscal 2026, bringing in $14.44M of $16.00M (90%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|
| Technology Fees | $8.80M | $11.25M | $12.59M | $14.44M | ||
| Device Sales | $837.03K | $814.23K | $1.20M | $1.56M | ||
| Service Related & Other Revenue | — | — | — | — | ||
| Total | $9.64M | $12.06M | $13.79M | $16.00M |
Biotricity brought in $16.00M from its two product and service lines in fiscal 2026, the year ended March 31, 2026. That was up 16.0% from $13.79M in fiscal 2025. Technology Fees was the largest at $14.44M (90.3%), ahead of Device Sales at $1.56M (9.7%).
Compared with fiscal 2025, Device Sales grew 29.9% to $1.56M and Technology Fees grew 14.7% to $14.44M. From fiscal 2023 to 2026, combined revenue from these lines grew from $9.64M to $16.00M, a compound annual growth rate of 18.4%. Technology Fees' share of the total fell from 91.3% to 90.3%.
Biotricity (BTCY) reports its revenue by product and service. In fiscal 2026, Technology Fees was its largest product and service line, bringing in $14.44M (90.3% of the total), followed by Device Sales at $1.56M (9.7%).
Technology Fees was Biotricity's largest product and service line in fiscal 2026, bringing in $14.44M, or 90.3% of the $16.00M total across its two product and service lines.
Device Sales grew faster than Technology Fees in fiscal 2026, up 29.9% from $1.20M to $1.56M. Technology Fees grew 14.7% to $14.44M.
Every figure comes from Biotricity's annual financial filings, as reported. Each line keeps the name Biotricity gives it, and years follow its fiscal calendar.
Biotricity's revenue by product and service goes back to fiscal 2021, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.